Fundraising Fox
Phase Genomics
Seattle, US · Founded 2015 · Delaware corporation · 14 employees on LinkedIn · 4 known investors
Find your way into Phase Genomics
Sign up to see every warm intro you have to Phase Genomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Phase Genomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Phase Genomics develops long-range genome sequencing technology based on proximity ligation, along with computational tools, for scientists studying cancer, inherited diseases, microbiomes, and biodiversity. It serves academic and research institutions and biopharmaceutical firms across life sciences, medicine, and agriculture.
Founders & leadership
Phase Genomics was founded in 2015 by Ivan Liachko and Shawn Sullivan.
IL
Ivan LiachkoCo-founder & CEOIvan Liachko is a molecular geneticist and genomicist with more than 20 years of experience in wet-lab and computational biology. He is the founder and CEO of Phase Genomics, a Seattle-based company established in 2015 that develops proximity-ligation-based long-range genome sequencing technology and computational tools for life sciences research.
SS
Shawn SullivanCo-Founder and AdvisorShawn Sullivan is co-founder and former CTO of Phase Genomics, a biotech company developing genome sequencing technology. He previously worked as a software engineer at Microsoft on Office products.
Investors · 4
Alliance of Angelslisted by Alliance of AngelsSeattle
How we know: Alliance of Angels's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Congruent Ventureslisted by Congruent VenturesSan Francisco · $100K – $5M
How we know: Congruent Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements$7.3M disclosed across 3 rounds · 2017–2024
- $1.5MraisedMar 2024 · 2 sources
Bill & Melinda Gates Foundation
Source ↗
▶$4.8MraisedMar 2023 · 13 investors · BiotechnologyRule 506(b)
▶$4.8MraisedMar 2023 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shawn SullivanExecutive Officer, Promoter
- Ivan LiachkoExecutive Officer, Director, Promoter
- Kayla YoungExecutive Officer
- Offering amount
- $6.6M
- Amount sold
- $4.8M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedNov 2017 · 4 investors · BiotechnologyRule 506(b)
▶$1MraisedNov 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ivan LiachkoExecutive Officer, Director, Promoter
- Shawn SullivanExecutive Officer, Promoter
- Offering amount
- $1.4M
- Amount sold
- $1M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
IDbyDNAScalable, high throughput DNA sequencing platforms.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
PacbPacific Biosciences manufactures consumables and reagent kits for long-read DNA and RNA sequencing platforms, serving genomics research and diagnostics labs.
Genomics PlcGenomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.
Polaris GenomicsPolaris Genomics is a Veteran-owned biotech startup mapping molecular biomarkers to develop objective, biologically-based diagnostics and novel therapeutics for mental health and neuropsychiatric conditions such as PTSD. It combines genomics and AI to advance precision mental health care.
Companies working in the same space as Phase Genomics.
In the news
Frequently asked questions
- What does Phase Genomics do?
- Phase Genomics develops long-range genome sequencing technology based on proximity ligation, along with computational tools, for scientists studying cancer, inherited diseases, microbiomes, and biodiversity. It serves academic and research institutions and biopharmaceutical firms across life sciences, medicine, and agriculture.
- Who founded Phase Genomics?
- Phase Genomics was founded by Ivan Liachko, Shawn Sullivan in 2015.
- Who are Phase Genomics's investors?
- Phase Genomics's investors include Alliance of Angels, Congruent Ventures, Hemi Ventures, Llc, Bill & Melinda Gates Foundation.
- How much funding has Phase Genomics raised?
- Phase Genomics has disclosed $7.3M raised across 3 rounds.
- Where is Phase Genomics headquartered?
- Phase Genomics is headquartered in Seattle, US.